# A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

> **NCT00750698** · PHASE2 · TERMINATED · sponsor: **Syndax Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00750698
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750698, "A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00750698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*